Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Autoimmune Monoclonal Antibody Market Growth From $76.59 Billion In 2026 To $104.57 Billion By 2030 At A CAGR Of 8.1%
The autoimmune monoclonal antibody market has experienced robust expansion in recent years. This market is projected to expand from $70.86 billion in 2025 to $76.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. Historically, the market’s growth has been fueled by factors such as the increasing prevalence of autoimmune diseases, the approval of new biologic drugs, the expansion of hospital infusion centers, advancements in chronic inflammation management, and the proliferation of specialty clinics.
The autoimmune monoclonal antibody market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $104.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth over the projected period include advancements in precision immunology, increased biosimilar penetration, the development of long-acting antibodies, the expansion of outpatient biologic administration, and the rise of personalized autoimmune therapies. Key trends anticipated during the forecast period encompass a greater embrace of targeted biologic therapies, the ongoing expansion of fully human antibody development, an increase in their application for chronic autoimmune conditions, a growing preference for subcutaneous administration, and a heightened emphasis on long-term disease control.
Get A Free Sample Report With In-Depth Market Insights:
Autoimmune Monoclonal Antibody Market Growth Factors Behind Sustained Expansion
The burgeoning requirement for biologics is anticipated to stimulate the expansion of the autoimmune monoclonal antibody market in the future. Biologics are defined as a class of medicinal substances originating from living entities or their parts, utilized for the therapy, prophylaxis, or identification of illnesses. The rising need for biologics primarily stems from their efficacy in managing intricate ailments like cancer, autoimmune disorders, and genetic conditions, particularly when conventional treatments prove less potent. Autoimmune monoclonal antibody improves biologic treatments through focused immune modulation, rendering them effective in controlling excessive immune reactions. These antibodies diminish the necessity for widespread immunosuppressive drugs by delivering exact therapy, thereby enhancing patient results and lessening adverse reactions. As an illustration, in June 2024, data from Cardinal Health Inc., a US-based healthcare company, indicated that there were 40 Food and Drug Administration (FDA) approved biosimilar products in 2023, with 25 commercially accessible in the US market, marking an increase from 33 biosimilar products in 2022. Consequently, the escalating demand for biologics is propelling the expansion of the autoimmune monoclonal antibody market.
Autoimmune Monoclonal Antibody Market Segment Landscape: Which Areas Lead Development?
The autoimmune monoclonal antibody market covered in this report is segmented –
1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular
3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions
Subsegments:
1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)
2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)
3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region
4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived
Autoimmune Monoclonal Antibody Market Industry Trends Fueling Future Revenue Growth
Key companies in the autoimmune monoclonal antibody sector are prioritizing the creation of innovative solutions, including biosimilar development, to elevate safety, efficacy, and quality. Biosimilar development entails producing biological products that are highly similar, safe, and effective to existing approved biologics. This is achieved through advanced biotechnology, stringent analytical testing, and clinical studies to demonstrate comparable quality, efficacy, and safety, crucial for regulatory approval. For instance, in February 2025, Biocon Biologics Limited, an India-based biopharmaceutical company, unveiled YESINTEK, a biosimilar designed to treat autoimmune conditions like Crohn’s disease, ulcerative colitis, and psoriasis. It functions by targeting and inhibiting the activity of interleukin-12 and interleukin-23 to decrease inflammation and regulate the immune response. Mimicking the reference product stelara, Yesintek aids in long-term disease management while improving patient access to biologic therapies.
Autoimmune Monoclonal Antibody Market Industry Leaders And Competitive Landscape
Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.
View The Full Autoimmune Monoclonal Antibody Market Report:
Autoimmune Monoclonal Antibody Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the autoimmune monoclonal antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
